- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | FDA approves Celltrion's biosimilar of J&J's Stelara | 3 | Seeking Alpha | ||
| Mi | Celltrion's Crohn's treatment set for February U.S. release | 1 | Korea Joongang Daily | ||
| Mi | Celltrion gets approval of Steqeyma from FDA | - | Korea Economic Daily | ||
| Mi | Celltrion Group Launches Celltrion BioSolutions to Enter CDMO Market | 2 | BusinessKorea | ||
| Di | Celltrion BioSolutions launched to venture into CDMO | 1 | Korea Economic Daily | ||
| Di | Celltrion launches CDMO subsidiary BioSolutions to achieve 3 trillion won sales goal | 2 | Korea Joongang Daily | ||
| Di | Celltrion launches CDMO subsidiary to drive growth beyond biosimilars | 1 | Korea Herald | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| Di | Celltrion establishes new subsidiary for CDMO business | 2 | Yonhap News | ||
| Mo | Celltrion's 4 new biosimilars win EU approval recommendation | 1 | Korea Economic Daily | ||
| Mo | Celltrion biosimilars recommended for EU approval | 2 | Korea Joongang Daily | ||
| Mo | European CHMP Recommends Approval for Four Celltrion Biosimilars | 2 | BusinessKorea | ||
| Mo | Celltrion erhält positive CHMP-Empfehlung zur Zulassung für drei Biosimilars in der Europäischen Union | 481 | Business Wire | Die drei Biosimilar-Kandidaten von Celltrion- Eydenzelt (Aflibercept), Stoboclo, Osenvelt (Denosumab) und Avtozma (Tocilizumab) erhalten die positive Empfehlung zur Zulassung des Ausschusses... ► Artikel lesen | |
| Mo | Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union | 321 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinions for Celltrion's three biosimilar candidates Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and... ► Artikel lesen | |
| 13.12. | Celltrion to allot cash, stock dividend at once | - | Korea Economic Daily | ||
| 13.12. | Celltrion to roll out record cash and stock dividends | 1 | Korea Joongang Daily | ||
| 13.12. | Celltrion to hand out record cash, stock dividends to shareholders | 3 | Yonhap News | ||
| 09.12. | Celltrion's asthma treatment greenlit for Canadian release | 1 | Korea Joongang Daily | ||
| 09.12. | Celltrion gets approval of Omlyclo in Canada | - | Korea Economic Daily | ||
| 09.12. | Health Canada Approves Celltrion's Omricleo for Allergic Asthma and Chronic Urticaria | 1 | BusinessKorea | ||
| 09.12. | Celltrion secures Canada's approval for Xolair biosimilar Omlyclo | 1 | Korea Herald |
Seite:
1 2 3 4 5 Weiter >>
132 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | CompuGroup, Evotec, Kion Group, Nagarro, ProSiebenSat.1 Media, TUI u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen CELLTRION INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.
